The cure time and outcomes for Double Hit Lymphoma (DHL) following CAR T-cell therapy like Yescarta can vary significantly between patients. Studies show that after two years, approximately 50% of people with DHL were still alive, with 40% showing no signs of disease progression.
CAR T-cell therapy has been a Show Full Answer
The cure time and outcomes for Double Hit Lymphoma (DHL) following CAR T-cell therapy like Yescarta can vary significantly between patients. Studies show that after two years, approximately 50% of people with DHL were still alive, with 40% showing no signs of disease progression.
CAR T-cell therapy has been a practice-changing development, offering a chance of cure for some patients whose lymphomas haven't responded to other treatments. It's important to note that DHL is often diagnosed at an advanced stage and can be refractory (non-responsive) to treatment. While CAR T-cell therapy represents a promising treatment option, the response varies by individual. Regular follow-up with your healthcare team is essential to monitor your specific response to treatment.
June 27, 2025
Join
Your Privacy Choices
